{"id":"sb204-4","safety":{"commonSideEffects":[{"rate":"null","effect":"Skin irritation"}]},"_chembl":{"chemblId":"CHEMBL2108676","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by releasing nitric oxide, which has antimicrobial and anti-inflammatory properties, to treat acne.","oneSentence":"SB204 4% is a topical nitric oxide-releasing agent.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:36.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT02667444","phase":"PHASE3","title":"P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2016-02-19","conditions":"Acne Vulgaris","enrollment":1330},{"nctId":"NCT02672332","phase":"PHASE3","title":"P3 Study in Acne Comparing Once Daily SB204 and Vehicle","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2016-02-22","conditions":"Acne Vulgaris","enrollment":1307},{"nctId":"NCT02242760","phase":"PHASE2","title":"P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2014-11","conditions":"Acne Vulgaris","enrollment":213},{"nctId":"NCT02798120","phase":"PHASE3","title":"P3 Long Term Safety Study of Once Daily SB204 in Acne","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2016-05-12","conditions":"Acne Vulgaris","enrollment":601},{"nctId":"NCT02581072","phase":"PHASE1","title":"A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2015-10","conditions":"Acne Vulgaris","enrollment":56},{"nctId":"NCT01844739","phase":"PHASE1","title":"A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2013-04","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT02250430","phase":"PHASE1","title":"A Phase 1 Study Assessing Local Cutaneous Effects of SB204","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2014-09","conditions":"Acne Vulgaris","enrollment":8},{"nctId":"NCT02801903","phase":"PHASE1","title":"Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2016-06-07","conditions":"Acne Vulgaris","enrollment":18},{"nctId":"NCT02164084","phase":"PHASE1","title":"A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2014-06","conditions":"Acne Vulgaris","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NVN1000"],"phase":"phase_3","status":"active","brandName":"SB204 4%","genericName":"SB204 4%","companyName":"Novan, Inc.","companyId":"novan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SB204 4% is a topical nitric oxide-releasing agent. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}